StockNews.AI
PAVM
StockNews.AI
19 days

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

1. PAVmed will host a business update on August 14, 2025. 2. CEO Lishan Aklog will present operational and growth strategy updates. 3. CFO Dennis McGrath will reveal Q2 2025 financial results. 4. PAVmed specializes in medical technology, diagnostics, and digital health sectors. 5. Subsidiary Lucid Diagnostics offers unique cancer detection tools.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming call may reveal positive developments leading to increased investor confidence, similar to past earnings boosts for medical technology firms that reported better-than-expected results.

How important is it?

The conference call may address significant updates that could influence investor perception and stock performance.

Why Short Term?

The company’s conference call is closely upcoming, making it likely that any positive news will impact share prices immediately.

Related Companies

LUCD
Conference Call and Webcast at 8:30 AM Eastern Time , /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com. About PAVmedPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform. For more and for more information about PAVmed, please visit pavmed.com. For more information about Lucid Diagnostics, please visit luciddx.com. For more information about Veris Health, please visit verishealth.com.  SOURCE PAVmed Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News